KDT 501

Drug Profile

KDT 501

Alternative Names: KDT501

Latest Information Update: 12 Jan 2016

Price : $50

At a glance

  • Originator KinDex Pharmaceuticals
  • Class Anti-inflammatories; Antihyperglycaemics; Cyclopentanes; Insulin sensitisers; Small molecules
  • Mechanism of Action GPR120 protein stimulants; Inflammasome modulators; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Inflammation

Most Recent Events

  • 30 Sep 2015 Biomarkers information updated
  • 01 Apr 2015 Phase-II clinical trials in Type-2 diabetes mellitus in USA (PO) (NCT02444910)
  • 25 Mar 2014 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top